Dr. Yaron Daniely is the CEO and President of Yissum. Before joining Yissum in 2017, he served for eight years as President, CEO and Director of Alcobra Ltd. Prior to his appointment at Alcobra, Yaron was President and CEO of NanoCyte, Inc (2004-2007), based in Caesarea, Israel, where he focused on developing transdermal delivery technologies.
Previously, Yaron held a number of leadership positions, including General Manager and VP of Business Development at Gamida Cell-Teva Joint Venture, Ltd, a joint venture company based in Jerusalem, Israel which acquired an exclusive license to develop and commercialize a Phase 3-stage cell therapy product for treatment of Leukemia and Lymphoma. Additionally, he co-founded and served as Director of Bioblast Ltd. (NASADQ:ORPN).
Yaron earned a B.Sc. in Biological Sciences from Florida International University, and a PhD from the Sackler Institute of Graduate Biomedical Sciences at the NYU School of Medicine. Following his doctoral program, Yaron served as an NIH Visiting Fellow in its Cell Biology section and as a Postdoctoral Fellow in the Department of Molecular Cell Biology at The Weizmann Institute for Science in Israel. Subsequently, he received an Executive MBA from the Technion-Israel Institute of Technology.
Yaron co-founded Israel’s first M.B.A. program specializing in Biomedical Management at the College of Management Academic Studies (Rishon LeZion, Israel) and has served as the program’s director since its inception.
Sharon Cohen has served as Yissum’s CFO since 2010, after first serving as Yissum’s Controller for four years. Sharon’s previous experience includes positions in the Finance department of the Jewish Agency and at KPMG Somekh Chaikin, a member firm of KPMG International.
Sharon is a certified public accountant (Israel) and holds a BA in Business Management and Accounting and an MBA (Cum Laude) from the Israel College of Management Academic Studies.
Tamir Huberman is Yissum’s Chief Information Officer (CIO) and oversees Yissum’s marketing activity. Previously, Tamir was Vice-President of Business Development, Computer Science and Director of IT at ITTN (Israel Technology Transfer Organization). In his capacity at Yissum, he also served on the Board of Directors at InnerEye and as an Observer on the board at BriefCam.
Tamir brings to Yissum over 20 years’ experience in deal negotiation, startup formation, and public speaking. He is responsible for implementation of various key IT platforms that serve the core systems of the company.
Prior to joining Yissum in 2004, Tamir was Co-Founder of Artigon; a member of the R&D team at Orgenics; and Head of IP and R&D at MedisEl. He holds an MSc. in structural biology and a BSc in biology from The Hebrew University of Jerusalem, a diploma in Computer & Electronics, and is continuing his MBA studies at the Hebrew University. He is also a certified Trainer of NLP from ABNLP.
Dr. Itzik Goldwaser is SVP of Alliances and Contracts Management at Yissum. Itzik has over 20 years of experience in the bio-pharmaceutical industry, spanning executive and R&D management roles in the biotechnology, chemical, and biological drug development markets.
Itzik has held a number of leadership positions, including Co-Founder, CEO, and President of NasVax from its founding in 2004 until 2010. Itzik joined NasVax from Sol-Gel Technologies, where he served as CTO and Chief Biologist.
Itzik earned his PhD in Biological Chemistry from the Weizmann Institute of Science, his M.Sc. in Medical Science from the Sackler School of Medicine at Tel Aviv University, and a B.Sc. in Chemistry from The Hebrew University of Jerusalem. Itzik is the co-owner of several registered patents in pharmacology and has authored numerous publications in this field.
Bob Trachtenberg joined Yissum in 2006 as its first General Counsel. In this role he manages all aspects of Yissum’s legal work, including technology licensing and intellectual property protection. An attorney with over 35 years of experience in the US and Israel, Bob previously served as General Counsel of Keryx Biopharmaceuticals (NASDAQ: KERX) and of Accent Software International.
He earned his JD from New York University and his BA from Binghamton University.
Aviv Shoher is Senior Vice-President of Business Development at Yissum and is responsible for developing and finalizing Yissum’s priority commercial projects. Aviv brings with him vast experience in the innovation ecosystem, and has a proven track record of accelerating the success of R&D commercialization through global partnerships with various stakeholders, including multinational corporations, government and private investors.
Prior to joining Yissum, Aviv served as CEO and founder of a number of portfolio companies including Gil Medical as well as VP of Business Development of the RAD BioMed Accelerator.
Aviv earned his MBA with a focus on Health Enterprise Management from Northwestern University’s Kellogg School of Management. In addition, he holds a Law degree from Tel Aviv University (TAU), as well as BA in economics from TAU.
Yoav Hirsch is a Senior Vice-President of Scouting, Ideation and Technology Evaluation at Yissum and is responsible for identifying beneficial research and promoting innovative collaborations primarily in the fields of life sciences and biotech, applied sciences, and computer science and engineering. A bio-medical engineer by training, Yoav brings with him over 10 years of experience in medical device product development and management.
Yoav served in the Israeli Airforce as a fighter pilot and flight instructor for 8 years and earned a BSc from Tel Aviv University as well as an MBA from the College of Management in Israel.
Dr. Eyal Emmanuel is a Senior Vice-President of Scouting, Ideation and Technology at Yissum and is responsible for translating research results into commercial ready technologies within the Robert H. Smith Faculty Agriculture, Food & the Environment. Eyal also serves as the Chief Technology Officer for Agrinnovation, an investment partnership founded by Yissum to nurture agricultural inventions originating from The Smith Faculty.
Prior to joining Evogene, Eyal served as a researcher promoting biomedical technologies at Life Science Research Israel, Israel's premier life sciences research center. Eyal holds a BSc in Agriculture from the Hebrew University and an MSc and PhD from the Weizmann Institute of Science. Eyal also holds an MBA from the College of Management in Israel with a concentration in Bio-Medical Management.
Ms. Markel joined Yissum in October 2008 from ProChon Biotech, where she headed the business development activities initiating and establishing joint projects with major companies in the field of sports medicine, in addition to negotiating distribution deals in Europe. Prior to that she served as a marketing strategy consultant to Invitrogen Ltd., a global provider and producer of advanced tools for biological research. She established the US sales and marketing operations of QuantomiX, an Israeli company, initiating the adoption of a cutting edge innovative technology in the field of electron microscopy by over 70 leading global pharmaceutical and biotechnology companies and major universities. Earlier in her career, she was a sales executive at Beckman Coulter Inc., a world leader in the production of scientific and diagnostic instrumentation for the life science markets, consulting on robotic systems for drug discovery. Ariela holds a B.Sc. (cum laude) and M.Sc. in biophysical chemistry from Ben Gurion University and an MBA from the joint international programme of the Kellogg School of Management at Northwestern University and Tel Aviv University.
Dr. Keynan joined Yissum in 2008, with a strong background in scientific, industrial & business strategy. She joined Yissum from RadBioMed, one of Israel's leading biomedical incubators, where as project manager she was responsible for the deal flow, evaluation and management assistance to the CEO. Prior to that she worked at Quark Pharma, one of Israel's top biopharmaceutical companies, where she was the metabolic cell-based bioassay manager. Dr. Keynan holds a Ph.D. in biochemistry from the Hebrew University Hadassah Medical School in Jerusalem, and spent four years as a postdoctoral fellow in the biochemistry and molecular biology department at Leeds University, UK.
Mr. Baron has over 15 years of management experience at both executive and entrepreneurial levels, with a background in early-stage medical and food-tech companies. Previously, he served as the CEO and co-founder of Ora Bio Ltd and SiL Vascular Ltd, and was the CEO of Bactusense technologies.; Mr. Baron has also worked with Healthcare Ventures, a fund focused on medical technology based companies. Mr. Baron Graduated the "Building Business Bridges' business school of international business at Tel Aviv University. He holds a BSc. in Agriculture from the faculty of agriculture and M.Sc. from the Weizmann institute.
Ms. Abramzon-Shmueli joined Yissum in 2004 and is responsible for the management and administration of Yissum’s extensive portfolio of intellectual property. The IP department activities include invention disclosures, prosecution of patent applications, inter-institutional agreements and coordinating of outside patent counsel operations.
Prior to joining Yissum, Ms. Abramzon-Shmueli worked at the Jerusalem Municipality’s tax department. She holds a Bachelor’s degree in Philosophy, and a Masters degree in History and Sociology of Science, with expertise in the history of Technology Transfer. Both degrees from the Hebrew University of Jerusalem.
Ms. Gallily joined Yissum in 2004 and oversees the professional aspects of Yissum's extensive patent portfolio and provide patent counselling and advice to support business activities. Ms Gallily’s 15 years of professional IP experience prior to joining Yissum include serving as in-house patent counsel at Keryx (NASDAQ: KERX) and as an attorney with a leading intellectual property firm for 15 years, where she focused on drafting and prosecuting patent applications in all fields of the life sciences. Ms Gallily holds an MSc in Physiology (neurobiology) from the Hebrew University and a diploma in organizational counselling from the College of Management.